Recent Quotes (30 days)

You have no recent quotes
chg | %

Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for TSE:LOR
+0.01 (0.28%)
May 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 3.57 - 3.62
52 week 2.74 - 8.33
Open 3.61
Vol / Avg. 4,875.00/12,185.00
Mkt cap 43.11M
P/E     -
Div/yield     -
EPS -1.17
Shares 12.11M
Beta 1.28
Inst. own     -
Aug 2, 2016
Q2 2016 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2016
Aptose Biosciences Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 10, 2016
Q1 2016 Aptose Biosciences Inc Earnings Call - Webcast
May 10, 2016
Q1 2016 Aptose Biosciences Inc Earnings Release
May 2, 2016
Aptose Biosciences Inc at Bloom Burton & Co. Healthcare Investor Conference
Mar 29, 2016
Q4 2015 Aptose Biosciences Inc Earnings Call - Webcast
Mar 29, 2016
Q4 2015 Aptose Biosciences Inc Earnings Release
Mar 14, 2016
Aptose Biosciences Inc at ROTH Conference - Webcast
Mar 7, 2016
Aptose Biosciences Inc at Cowen Health Care Conference

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -108.61% -44.57%
Return on average equity -122.37% -48.90%
Employees 22 -
CDP Score - -


5955 Airport Rd Suite 228
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links


Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Avanish Vellanki Senior Vice President, Chief Business Officer
Denis R. Burger Ph.D. Independent Director
Age: 70
Erich M. Platzer M.D.,Ph.D. Independent Director
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director